December 8, 2006 Dear Mr. Smith:
Mahalo for taking the time to write to me to voice your opposition to the Dietary Supplement and Non-Prescription Drug Consumer Protection Act (S.3546). I appreciate your interest in this important matter. As you may know, S. 3546 would amend the Federal Food, Drug and Cosmetic Act to require a manufacturer, distributor or packager whose name appears on the label of a nonprescription drug or dietary supplement marketed in the U.S. to submit to the Secretary of Health and Human Services any report received of serious adverse effect of any drug along with any related medical information. They must then retain these records for six years, and the records may be inspected upon request. S. 3546 also contains provisions that would make reporting adverse events easier and would allow the Secretary to issue exemptions if the public health would not be affected. The bill was introduced in the Senate on June 21, 2006 and was subsequently referred to the Committee on Health, Education, Labor and Pensions. There is no vote scheduled on the Senate floor at this time. There is currently no similar legislation in the House of Representatives. However, if the House does decide to take up this issue, I will be sure to keep your thoughts in mind. Again, mahalo for writing to me. Please do not hesitate to contact me with your questions or concerns in the future Sincerely, Neil Abercrombie Member of Congress -- The Silver List is a moderated forum for discussing Colloidal Silver. Instructions for unsubscribing are posted at: http://silverlist.org To post, address your message to: [email protected] Address Off-Topic messages to: [email protected] The Silver List and Off Topic List archives are currently down... List maintainer: Mike Devour <[email protected]>
